B
Bull
Bull · 25%DMAA
$10.91
Szenariopreis
$10.750
-0.010 (-0.09%)Zum Schluss
Loading chart…
- High
- 10.750
- Open
- 10.750
- VWAP
- 10.75
- Vol
- 4.23K
- Mkt Cap
- —
- Low
- 10.740
- Amount
- 45.44K
- EV/EBITDA, TTM
- 0.00
Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues.
AI analysis of Drugs Made In America Acquisition Corp (DMAA)
holdCurrently, DMAA is not a strong buy due to its high P/E ratio of 55.63 and a low current ratio of 0.02, indicating potential liquidity issues. The RSI is at 61.24, suggesting it is nearing overbought territory, which may limit upside potential in the short term.
Bewertungskennzahlen
The current forward P/E ratio for Drugs Made In America Acquisition Corp (DMAA) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for DMAA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding DMAA
DMAA FAQ — answered by Alphio AI
Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues. It operates in the Financials sector.
Currently, DMAA is not a strong buy due to its high P/E ratio of 55.63 and a low current ratio of 0.02, indicating potential liquidity issues. The RSI is at 61.24, suggesting it is nearing overbought territory, which may limit upside potential in the short term.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.